Insight
LC-MS as an Essential Tool for GLP-1/GIP Drug DMPK Studies
GLP 1 and GIP peptide therapeutics are reshaping metabolic disease pipelines, but they also introduce significant bioanalytical and DMPK challenges. This poster highlights how modern LC MS and HRMS approaches are being applied across DMPK phases to overcome sensitivity, selectivity, and metabolite identification hurdles unique to therapeutic peptides. Using real examples from GLP 1/GIP programs, it demonstrates why advanced LC MS strategies are becoming essential, not optional, for confident PK, metabolite profiling, and translational decision making in obesity and T2D drug development.
Complete the form to access this poster.
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
